EUVIMEDEUVIMED entdecken
CrossrefInfokarte

DSPE-Based Ligand-Cross-Linked Lipid Nanoparticles for BBB/BBTB Transport and Glioma Targeting

Menghuan Tang, Yanyu Huang, Qiufang Zong, Ruohao Fan, Md Saiful I. Chowdhury, Nhung Thi Hong Au, Kelsey Jane Racacho, Athena Sabaten Aragon, Francisco Javier Castaneda, Adam Abdelkhaleq, Tzu-Yin Lin, Yuanpei Li

ACS Nano Medicine · 2026-11-11 · 1 (10) · 2703-2715

DOI: 10.1021/acsnanomed.6c00185 ↗
AbstractBibliografische Angaben

Abstract

Abstract Insufficient drug accumulation at intracranial tumor sites remains a major obstacle to effective glioma therapy, primarily due to restricted transport across the blood–brain barrier (BBB)/blood–brain tumor barrier (BBTB) and limited active targeting to glioma cells. Here, we report DSPE-based ligand-cross-linked lipid nanoparticles (DBLC LNPs) that integrate lipid-interface engineering, ligand cross-linking, and sequential glioma targeting within a single nanoparticle platform. In this design, maltobionic acid (MA)-functionalized DSPE was incorporated to promote glucose transporter 1 (GLUT1)-mediated BBB/BBTB transport, while 3-(propionamido)phenylboronic acid (PAPBA)-functionalized DSPE was introduced to recognize sialic acid-containing glycans on glioma cell surfaces. Compared with many complex multifunctional brain-tumor nanocarriers, this DSPE-based lipid-interface design introduces transport and recognition through defined lipid-ligand conjugates, thereby reducing synthetic complexity while maintaining formulation tunability and cargo-loading flexibility. Microfluidic technology further enabled controlled and reproducible preparation of DBLC LNPs, supporting their formulation compatibility and translational potential. In an orthotopic glioma model, vincristine (VCR)-loaded DBLC LNPs significantly suppressed glioma growth and prolonged survival. Magnetic resonance imaging (MRI)-based 3D reconstruction analysis of brain tumor further showed that DBLC LNPs@VCR inhibited tumor growth more effectively than free VCR, with tumor volume more than 6-fold lower than that in the free VCR group. Together, this study establishes a DSPE-based ligand-cross-linked LNP platform that combines sequential BBB/BBTB transport, drug-loading capacity, and formulation compatibility to improve therapeutic delivery for glioma treatments.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →